scholarly journals Preliminary Study of the Effect of Stereotactic Body Radiotherapy (SBRT) on the Immune System in Lung Cancer Patients Unfit for Surgery: Immunophenotyping Analysis

2018 ◽  
Vol 19 (12) ◽  
pp. 3963 ◽  
Author(s):  
Arturo Navarro-Martín ◽  
Isabel Galiana ◽  
Miguel Berenguer Frances ◽  
Jon Cacicedo ◽  
Rut Cañas Cortés ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Immune System ◽  
Cancer Patients ◽  
Stereotactic Body Radiotherapy ◽  
Immune Cell ◽  
Suppressor Cells ◽  
Host Immune System ◽  
Lung Cancer Patients ◽  
Specific Increase ◽  
Relevant Finding

An immunophenotyping analysis was performed in peripheral blood samples from seven patients with lung cancer unfit for surgery treated with stereotactic body radiotherapy (SBRT). The objective was to characterize the effect of SBRT on the host immune system. Four patients received 60 Gy (7.5 Gy × 8) and three 50 Gy (12.5 Gy × 4). Analyses were performed before SBRT, 72 h after SBRT, and at one, three, and six months after the end of SBRT. Of note, there was a specific increase of the immunoactive component of the immune system, with elevation of CD56+highCD16+ natural killer (NK) cells (0.95% at baseline to 1.38% at six months), and a decrease of the immunosuppressive component of the immune system, with decreases of CD4+CD25+Foxp3+CDA5RA− regulatory T cells (4.97% at baseline to 4.46% at six months), granulocytic myeloid-derived suppressor cells (G-MDSCs) (from 66.1% at baseline to 62.6% at six months) and monocytic (Mo-MDSCs) (8.2% at baseline to 6.2% at six months). These changes were already apparent at 72 h and persisted over six months. SBRT showed an effect on systemic immune cell populations, which is a relevant finding for supporting future combinations of SBRT with immunotherapy for treating lung cancer patients.

Stereotactic body radiotherapy in non-operable lung cancer patients

2016 ◽  
Vol 18 (11) ◽  
pp. 1158-1159
Author(s):  
R. E. Vadalà ◽  
A. Santacaterina ◽  
A. Sindoni ◽  
A. Platania ◽  
A. Arcudi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Stereotactic Body Radiotherapy ◽  
Lung Cancer Patients

scholarly journals Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Liyuan Song ◽  
Xianhui Wang ◽  
Wang Cheng ◽  
Yi Wu ◽  
Min Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Molecular Markers ◽  
Cancer Patients ◽  
Targeted Therapies ◽  
Poor Prognosis ◽  
Immune Cell ◽  
Clinicopathological Parameters ◽  
Cancer Specific Survival ◽  
Lung Cancer Patients ◽  
Favorable Prognosis

Abstract Background In recent years, immunotherapies and targeted therapies contribute to population-level improvement in NSCLC cancer-specific survival, however, the two novel therapeutic options have mainly benefit patients containing mutated driven genes. Thus, to explore other potential genes related with immunity or targeted therapies may provide novel options to improve survival of lung cancer patients without mutated driven genes. CTSF is unique in human cysteine proteinases. Presently, CTSF has been detected in several cell lines of lung cancer, but its role in progression and prognosis of lung cancer remains unclear. Methods CTSF expression and clinical datasets of lung cancer patients were obtained from GTEx, TIMER, CCLE, THPA, and TCGA, respectively. Association of CTSF expression with clinicopathological parameters and prognosis of lung cancer patients was analyzed using UALCAN and Kaplan–Meier Plotter, respectively. LinkedOmics were used to analyze correlation between CTSF and CTSF co-expressed genes. Protein–protein interaction and gene–gene interaction were analyzed using STRING and GeneMANIA, respectively. Association of CTSF with molecular markers of immune cells and immunomodulators was analyzed with Immunedeconv and TISIDB, respectively. Results CTSF expression was currently only available for patients with NSCLC. Compared to normal tissues, CTSF was downregulated in NSCLC samples and high expressed CTSF was correlated with favorable prognosis of NSCLC. Additionally, CTSF expression was correlated with that of immune cell molecular markers and immunomodulators both in LUAD and LUSC. Noticeably, high expression of CTSF-related CTLA-4 was found to be associated with better OS of LUAD patients. Increased expression of CTSF-related LAG-3 was related with poor prognosis of LUAD patients while there was no association between CTSF-related PD-1/PD-L1 and prognosis of LUAD patients. Moreover, increased expression of CTSF-related CD27 was related with poor prognosis of LUAD patients while favorable prognosis of LUSC patients. Conclusions CTSF might play an anti-tumor effect via regulating immune response of NSCLC.

scholarly journals Stereotactic body radiotherapy (SBRT) for non- pathologically diagnosed lung cancer patients

2012 ◽  
Vol 2 (3) ◽  
Author(s):  
Matthew M Harkenrider ◽  
Matthew H Bertke ◽  
Neal E Dunlap ◽  
Anthony E Dragun
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Stereotactic Body Radiotherapy ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document